Abstract 3051
Background
A better identification of patients who are more likely to benefit from immune checkpoint inhibitors is warranted in advanced non-small cell lung cancer (NSCLC). In resent preclinical study, obesity was associated with increased efficacy of PD-1/PD-L1 blockage. Herein, we conducted a retrospective study to investigate the prognostic accuracy of body mass index (BMI) and computed tomography-defined fat area in patients with advanced NSCLC treated with nivolumab.
Methods
We retrospectively analyzed patients with advanced NSCLC who received nivolumab at our institute between January 2016 and January 2019. Clinical data including BMI, visceral fat area (VFA) and subcutaneous fat area (SFA), and progression free survival (PFS) were collected. Treatment outcome of nivolumab was assessed according to the Response Evaluation Criteria in Solid Tumors, version 1.1.
Results
In total, 126 patients were included in this study. High VFA (≥100cm2) were significantly associated with longer PFS, whereas high SFA (≥100cm2) and high BMI (≥25) were not. The objective response rates were higher in patients with high VFA than in those with low VFA (39% versus 19%; [P = 0.027], respectively). In multivariate analysis, high VSA (hazard ratio: 0.61, 95% confidence interval: 0.40–0.93; [P = 0.022]) and better PS (hazard ratio:0.35, 95% confidence interval: 0.19–0.68; [P = 0.003]) were identified as an independent predictor of longer PFS in patients treated with nivolumab.
Conclusions
In patients with advanced NSCLC who received nivolumab, high VFA were independent predictors of nivolumab efficacy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Kobe City Medical Center General Hospital.
Funding
Has not received any funding.
Disclosure
Y. Sato: Speaker Bureau / Expert testimony: Ono Pharmaceutical Co., Ltd. D. Fujimoto: Speaker Bureau / Expert testimony: Ono Pharmaceutical Co., Ltd. K. Hosoya: Speaker Bureau / Expert testimony: Ono Pharmaceutical Co., Ltd. All other authors have declared no conflicts of interest.
Resources from the same session
1357 - Upfront atezolizumab chemoimmunotherapy-associated Immune-related adverse events in patients with advanced non-small cell lung cancer
Presenter: Francis Mogollon-Duffo
Session: Poster Display session 1
Resources:
Abstract
1851 - Nivolumab-induced and radiation recall pneumonitis in patients with non-small cell lung cancer: a multicenter real world analysis of 669 patients
Presenter: Nobuaki Mamesaya
Session: Poster Display session 1
Resources:
Abstract
851 - Retrospective analysis of immunotherapy prognostic scores in advanced NSCLC at Nottingham University Hospitals (UK)
Presenter: Cristina Lopez Escola
Session: Poster Display session 1
Resources:
Abstract
3639 - Applicability of lung immune prognostic index (LIPI) to predict efficacy of first-line pembrolizumab in advanced non-small-cell lung cancer (NSCLC)
Presenter: Xabier Mielgo Rubio
Session: Poster Display session 1
Resources:
Abstract
2950 - Delayed Onset Immune Related Adverse Effects (IRAEs) of Pembrolizumab in Non-Small Cell Lung Cancer
Presenter: Haixi Yan
Session: Poster Display session 1
Resources:
Abstract
3659 - Clinical implication of multiplex IHC and serologic biomarkers on Hyperprogression in NSCLC patients receiving Immune checkpoint blockers in real world.
Presenter: Joori Kim
Session: Poster Display session 1
Resources:
Abstract
4882 - Local ablative treatment and treatment beyond progression for oligo-progression in stage IV non-small cell lung cancer after tumor response to anti-PD1 treatment
Presenter: Florian Guisier
Session: Poster Display session 1
Resources:
Abstract
1358 - Atezolizumab in combination with chemotherapy for first-line treatment of advanced non-small cell lung cancer: A systematic review and meta-analysis of randomized controlled trials (RCTs)
Presenter: Francis Mogollon-Duffo
Session: Poster Display session 1
Resources:
Abstract
2170 - Prognostic Impact of Metastatic Sites for Pembrolizumab Efficacy as First-line therapy in Patients with PD-L1 tumor proportion score (TPS) ≥ 50% Advanced Non–Small Cell Lung Cancer: A Retrospective Multicenter Study
Presenter: Hayato Kawachi
Session: Poster Display session 1
Resources:
Abstract
3409 - Effect and safety of immune checkpoint inhibitors for brain metastases from non-small cell lung cancer
Presenter: Toshihiko Iuchi
Session: Poster Display session 1
Resources:
Abstract